Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD

Recruiting now · Phase 3

Conditions studied: Glomerulonephritis, IGA

In brief

The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.

Key facts

Study ID

NCT05510323

Run by

Air Force Military Medical University, China

People needed

208

Starts

2024-02-01

Expected to finish

2028-08-01

Last updated by the study team

2024-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy-proven IgA nephropathy;
• Proteinuria ≥1.0g/day while receiving maximum tolerated dose of RAS blockade;
• Estimated glomerular filtration rate 15-60 ml/min/1.73/m2.

You may not qualify if…

• Indication or contraindication for immunosuppressive therapy with corticosteroids
• Use of corticosteroids and other immunosuppressive drugs within the last 1 year
• Current unstable kidney function for other reasons
• Under 18 years old
• Patients with secondary IgAN
• Patients who are unlikely to comply with the study protocol in the view of the treating physician

Where it is running

• AFMMU — Xi'an, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.